Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid α-glucosidases in human fibroblasts and HepG2 cells

doi:10.1016/0009-8981(89)90148-4

Clinica Chimica Acta

Volume 182, Issue 1, 15 June 1989, Pages 41-52

https://doi.org/10.1016/0009-8981(89)90148-4 Get rights and content

Abstract

The effect of the glucose analogue N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of α-glucosidases was studied in human fibroblasts and HepG2 cells. BAY m 1099 inhibits neutral and acid α-glucosidase activities of both cell types in a dosage-dependent and reversible manner. Inhibition of endoplasmic reticulum glucosidases I and/or II is suggested by delayed processing of lysosomal (acid) α-glucosidase. Competitive inhibition of mature acid α-glucosidase leads to lysosomal accumulation of glycogen as in glycogenosis type II. There seems to be little risk, however, of inducing this storage disorder when using the drug in a dose of 50 mg per os for treatment of type II diabetes. In high doses, the drug may prove useful for studying the pathogenesis of glycogenosis type II in vitro or in animal models.

References (29)

U Fuhrmann et al.
Inhibitors of oligosaccharide processing
Biochim Biophys Acta
(1985)
P Lemansky et al.
Cathepsin D and β-hexosaminidase synthesized in the presence of 1-deoxynojirimycin accumulate in the endoplasmic reticulum
J Biol Chem
(1984)
RF Arakaki et al.
Effects of castanospermine and 1-deoxynojirimycin on insulin receptor biogenesis: evidence for a role of glucose removal from core oligosaccharides
J Biol Chem
(1987)
JP Chambers et al.
Nojirimycin: a potent inhibitor of purified lysosomal alpha-glucosidase from human liver
Biochem Biophys Res Commun
(1982)
OH Lowry et al.
Protein measurement with the folin phenolreagent
J Biol Chem
(1951)
H Galjaard et al.
A method for rapid prenatal diagnosis of Glycogenosis II (Pompe's disease)
Clin Chim Acta
(1973)
A Hasilik et al.
Biosynthesis of lysosomal enzymes in fibroblasts: synthesis as precursors of higher molecular weight
J Biol Chem
(1980)
AJJ Reuser et al.
Defects in synthesis, phosphorylation, and maturation of acid α-glucosidase in glycogenosis type II
J Biol Chem
(1985)
AT Van Der Ploeg et al.
Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid α-glucosidase
J Neurol Sci
(1987)
B Lembcke et al.
Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro
Digestion
(1985)

RH Taylor et al.

Regulation of the absorption of dietary carbohydrate in man by two new glucosidase inhibitors

Gut

(1986)

G Sachse et al.

Effect of the α-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics

Diabetologia

(1979)

J Arends et al.

Smoothing effect of a new α-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients

Horm Metabol Res

(1986)

N Katsilambros et al.

A doubleblind study on the efficacy and tolerance of a new α-glucosidase inhibitor in type-2 diabetics

Arzneim-Forsch/Drug Res

(1986)

Cited by (15)

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid α-glucosidase (alglucosidase alfa): Insight into the complex formation mechanism
2008, Clinica Chimica Acta
Recently, enzyme enhancement therapy (EET) for Pompe disease involving imino sugars, which act as potential inhibitors of acid α-glucosidases in vitro, to improve the stability and/or transportation of mutant acid α-glucosidases in cells was studied and attracted interest. However, the mechanism underlying the molecular interaction between the imino sugars and the enzyme has not been clarified yet.
We examined the inhibitory and binding effects of four imino sugars on a recombinant human acid α-glucosidase, alglucosidase alfa, by means of inhibition assaying and isothermal titration calorimetry (ITC). Furthermore, we built structural models of complexes of the catalytic domain of the enzyme with the imino sugars bound to its active site by homology modeling, and examined the molecular interaction between them.
All of the imino sugars examined exhibited a competitive inhibitory action against the enzyme, 1-deoxynojirimycin (DNJ) exhibiting the strongest action among them. ITC revealed that one compound molecule binds to one enzyme molecule and that DNJ most strongly binds to the enzyme among them. Structural analysis revealed that the active site of the enzyme is almost completely occupied by DNJ.
These biochemical and structural analyses increased our understanding of the molecular interaction between a human acid α-glucosidase and imino sugars.
Sugar-mimic glycosidase inhibitors: Natural occurrence, biological activity and prospects for therapeutic application
2000, Tetrahedron Asymmetry
Alkaloids mimicking the structures of monosaccharides are now believed to be widespread in plants and microorganisms, and these sugar mimics inhibit glycosidases because of a structural resemblance to the sugar moiety of the natural substrate. Naturally occurring sugar mimics with a nitrogen in the ring are classified into five structural classes: polyhydroxylated piperidines, pyrrolidines, indolizidines, pyrrolizidines and nortropanes. Glycosidases are involved in a wide range of important biological processes, such as intestinal digestion, post-translational processing of glycoproteins and the lysosomal catabolism of glycoconjugates. The realization that alkaloidal sugar mimics might have enormous therapeutic potential in many diseases such as viral infection, cancer and diabetes has led to increasing interest and demand for these compounds. Most of these effects can be shown to result from the direct or indirect inhibition of glycosidases. The glycosphingolipid (GSL) storage diseases are relatively rare hereditary disorders that are severe in nature and frequently fatal. Possible strategies for the treatment of these lysosomal storage diseases include enzyme replacement therapy, gene therapy and substrate deprivation. Recently, quite a new therapy for lysosomal storage diseases has been reported, namely a ‘chemical chaperone therapy’ for Fabry disease. In this report, the structural basis for the specificity of inhibition of alkaloidal sugar mimics and their current and potential application to biomedical problems will be reviewed.
Quantitative relationship of lysosomal glycogen accumulation to lysosomal α-glucosidase inhibition in castanospermine-treated rats
1991, Biochemical Pharmacology
To quantitatively examine the relationship between lysosomal acid α-glucosidase (LAAG, α-d-glucoside glucohydrolase, EC 3.2.1.20) inhibition and glycogen accumulation, rats were treated with castanospermine (CS), and liver lysosomal/mitochondrial fractions were analyzed for glycogen content and LAAG activity. Liver lysosomal glycogen accumulation positively correlated (r = 0.90) with the amount of LAAG inhibition when inhibition was about 50% or greater. Glycogen did not accumulate when LAAG inhibition was less than 50%. The route of CS administration had little effect on the amount of LAAG inhibition observed. In rats killed 17 hr after CS administration, the doses estimated to cause 50% LAAG inhibition were 0.77, 0.11, and 0.22 mg/kg for i.p., i.v., and oral administration respectively. After 89% inhibition of LAAG activity with a single oral dose of 10 mg CS/kg, LAAG activity returned to 50% of normal value in about 2.5 days. Accumulated glycogen disappeared as LAAG activity recovered. Surprisingly, twelve daily CS doses of 1 mg/kg had only a small cumulative effect on LAAG inhibition and did not cause more glycogen accumulation than a single dose.
Design and Synthesis of Labystegines, Hybrid Iminosugars from LAB and Calystegine, as Inhibitors of Intestinal α-Glucosidases: Binding Conformation and Interaction for ntSI
2015, Journal of Organic Chemistry
α-1-C-Butyl-1,4-Dideoxy-1,4-Imino-L-Arabinitol as a second-Generation iminosugar-based oral α-Glucosidase inhibitor for improving postprandial hyperglycemia
2012, Journal of Medicinal Chemistry
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
2012, Journal of Pharmacology and Experimental Therapeutics

View all citing articles on Scopus

View full text

Research communicationEffects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid α-glucosidases in human fibroblasts and HepG2 cells

Abstract

Biochim Biophys Acta

J Biol Chem

J Biol Chem

Biochem Biophys Res Commun

J Biol Chem

Clin Chim Acta

J Biol Chem

J Biol Chem

J Neurol Sci

Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro

Digestion

Regulation of the absorption of dietary carbohydrate in man by two new glucosidase inhibitors

Gut

Effect of the α-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics

Diabetologia

Smoothing effect of a new α-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients

Horm Metabol Res

A doubleblind study on the efficacy and tolerance of a new α-glucosidase inhibitor in type-2 diabetics

Arzneim-Forsch/Drug Res

Research communication
Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid α-glucosidases in human fibroblasts and HepG2 cells